Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 11;23(1):122.
doi: 10.1186/s12880-023-01088-1.

Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC

Affiliations

Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC

Rong Wen et al. BMC Med Imaging. .

Abstract

Objectives: To compare the inter-modality consistency and diagnostic performances of the contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) and contrast-enhanced computed tomography (CECT) LI-RADS in patients at risk for hepatocellular carcinoma (HCC), so as to help clinicians to select a more appropriate modality to follow the focal liver lesions (FLLs).

Methods: This retrospective study included untreated 277 FLLs from 247 patients who underwent both CEUS and CECT within 1 month. The ultrasound contrast medium used was SonoVue. FLL categories were independently assigned by two ultrasound physicians and two radiologists using CEUS LI-RADS v2017 and CECT LI-RADS v2018, respectively. The diagnostic performances of CEUS and CECT LI-RADS were evaluated using sensitivity, specificity, positive predictive value (PPV), and negative predictive value. Cohen's Kappa was employed to evaluate the concordance of the LI-RADS category.

Results: The inter-modality consistency for CEUS and CECT LI-RADS was 0.31 (p < 0.001). HCC was more frequently observed in CECT LR-3 and LR-4 hepatic lesions than in CEUS (7.3% vs. 19.5%, p < 0.001). The specificity and PPV of CEUS and CECT LR-5 for the diagnosis of HCC were 89.5%, 95.0%, and 82.5%, 94.4%, respectively. The sensitivity of CEUS LR-5 + LR-M for the diagnosis of hepatic malignancies was higher than that of CECT (93.7% vs. 82.7%, p < 0.001). The specificity and PPV of CEUS LR-M for the diagnosis of non-HCC malignancies were lower than those of CECT (59.7% vs. 95.5%, p < 0.001; 23.4% vs. 70.3%, p < 0.001).

Conclusions: The inter-modality consistency between the CEUS and CECT LI-RADS categories is fair. CEUS LI-RADS was more sensitive than CECT LI-RADS in terms of identifying hepatic malignancies, but weaker in terms of separating HCC from non-HCC malignancies.

Keywords: Computed tomography; Hepatocellular carcinoma; Liver Imaging Reporting and Data System; Ultrasonography.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
LI-RADS rating criteria. (a) and (b) show the diagnostic tables of CEUS and CECT, respectively. LI-RADS = Liver Imaging Reporting and Data System; CEUS = contrast-enhanced ultrasound; CECT = contrast-enhanced computed tomography
Fig. 2
Fig. 2
A lesion in segment 4 of the liver that was classified as LR-5 via CEUS and LR-4 via CECT, and eventually pathologically confirmed as HCC in a man with chronic hepatitis B. (a) Conventional ultrasound showed a hypoechoic mass measuring 2.6 × 1.8 cm in segment 4 of the liver. (b) CEUS displayed hyperenhancement in the arterial phase and mild washout in the portal (c) and late (d) phases. (e) Nonenhanced CT displayed a hypodense mass measuring 2.6 × 1.6 cm in segment 4 of the liver. (f) CECT showed isoenhancement in the arterial phase and washout in the portal (g) and late (h) phases
Fig. 3
Fig. 3
A lesion in segment 5 of the liver that was classified as LR-M via CEUS, LR-5 via CECT, and eventually pathologically confirmed as HCC in a man with hepatitis B-related cirrhosis. (a) Conventional ultrasound showed a hypoechoic mass measuring 3.2 × 2.1 cm in segment 5 of the liver. (b) CEUS displayed hyperenhancement in the arterial phase. (c) CEUS displayed early washout (42 s after injection) in the portal phase and (d) mild washout in the late phase. (e) Nonenhanced CT showed a hypodense mass measuring 2.9 × 2.8 cm in segment 5 of the liver. (f) CECT showed hyperenhancement in the arterial and portal (g) phases and washout in the late (h) phase with a visible enhancing capsule

Similar articles

References

    1. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, staging, and management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the study of Liver Diseases. Hepatology. 2018;68(2):723–50. doi: 10.1002/hep.29913. - DOI - PubMed
    1. European Association for the Study of the Liver Electronic address eee, European Association for the study of the L: EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi: 10.1016/j.jhep.2018.03.019. - DOI - PubMed
    1. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, et al. Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74. doi: 10.1007/s12072-010-9165-7. - DOI - PMC - PubMed
    1. Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, et al. Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018;289(3):816–30. Liver Imaging Reporting and Data System (LI-RADS). - PMC - PubMed
    1. Tang A, Singal AG, Mitchell DG, Hecht EM, Fowler KJ, Kulik L, Parikh ND, Kono Y, Sirlin CB. Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2019;17(7):1228–38. doi: 10.1016/j.cgh.2018.10.014. - DOI - PubMed

Publication types

MeSH terms